Anti-LIPM/ LIPL3/ bA304I5.1 functional antibody

Anti-LIPM/ LIPL3/ bA304I5.1 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LIPM/LIPM products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1075-Ab-1/ GM-Tg-hg-SE1075-Ab-2Anti-Human LIPM monoclonal antibodyHuman
GM-Tg-rg-SE1075-Ab-1/ GM-Tg-rg-SE1075-Ab-2Anti-Rat LIPM monoclonal antibodyRat
GM-Tg-mg-SE1075-Ab-1/ GM-Tg-mg-SE1075-Ab-2Anti-Mouse LIPM monoclonal antibodyMouse
GM-Tg-cynog-SE1075-Ab-1/ GM-Tg-cynog-SE1075-Ab-2Anti-Cynomolgus/ Rhesus macaque LIPM monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1075-Ab-1/ GM-Tg-felg-SE1075-Ab-2Anti-Feline LIPM monoclonal antibodyFeline
GM-Tg-cang-SE1075-Ab-1/ GM-Tg-cang-SE1075-Ab-2Anti-Canine LIPM monoclonal antibodyCanine
GM-Tg-bovg-SE1075-Ab-1/ GM-Tg-bovg-SE1075-Ab-2Anti-Bovine LIPM monoclonal antibodyBovine
GM-Tg-equg-SE1075-Ab-1/ GM-Tg-equg-SE1075-Ab-2Anti-Equine LIPM monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1075-Ab-1/ GM-Tg-hg-SE1075-Ab-2; GM-Tg-rg-SE1075-Ab-1/ GM-Tg-rg-SE1075-Ab-2;
GM-Tg-mg-SE1075-Ab-1/ GM-Tg-mg-SE1075-Ab-2; GM-Tg-cynog-SE1075-Ab-1/ GM-Tg-cynog-SE1075-Ab-2;
GM-Tg-felg-SE1075-Ab-1/ GM-Tg-felg-SE1075-Ab-2; GM-Tg-cang-SE1075-Ab-1/ GM-Tg-cang-SE1075-Ab-2;
GM-Tg-bovg-SE1075-Ab-1/ GM-Tg-bovg-SE1075-Ab-2; GM-Tg-equg-SE1075-Ab-1/ GM-Tg-equg-SE1075-Ab-2
Products NameAnti-LIPM monoclonal antibody
Formatmab
Target NameLIPM
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LIPM benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1075-Ag-1Recombinant multi-species LIPM/ LIPL3/ bA304I5.1 protein
    ORF Viral VectorpGMLP001785human LIPM Lentivirus plasmid
    ORF Viral VectorvGMLP001785human LIPM Lentivirus particle
    ORF Viral VectorpGMLPm002035mouse Lipm Lentivirus plasmid
    ORF Viral VectorvGMLPm002035mouse Lipm Lentivirus particle


    Target information

    Target IDGM-SE1075
    Target NameLIPM
    Gene ID340654,694146,610497,101092791,517290,100071658
    Gene Symbol and SynonymsbA304I5.1,LIPL3,LIPM
    Uniprot AccessionQ5VYY2
    Uniprot Entry NameLIPM_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000173239
    Target ClassificationN/A

    The target: LIPM, gene name: LIPM, also named as LIPL3, bA304I5.1. Predicted to enable lipoprotein lipase activity. Predicted to be involved in cornification. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.